1
|
Bedini A, Boutin JA, Legros C, Zlotos DP, Spadoni G. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey. J Pineal Res 2024; 76:e12953. [PMID: 38682544 DOI: 10.1111/jpi.12953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 03/05/2024] [Accepted: 03/24/2024] [Indexed: 05/01/2024]
Abstract
The search for melatonin receptor agonists formed the main part of melatonin medicinal chemistry programs for the last three decades. In this short review, we summarize the two main aspects of these programs: the development of all the necessary tools to characterize the newly synthesized ligands at the two melatonin receptors MT1 and MT2, and the medicinal chemist's approaches to find chemically diverse ligands at these receptors. Both strategies are described. It turns out that the main source of tools were industrial laboratories, while the medicinal chemistry was mainly carried out in academia. Such complete accounts are interesting, as they delineate the spirits in which the teams were working demonstrating their strength and innovative character. Most of the programs were focused on nonselective agonists and few of them reached the market. In contrast, discovery of MT1-selective agonists and melatonergic antagonists with proven in vivo activity and MT1 or MT2-selectivity is still in its infancy, despite the considerable interest that subtype selective compounds may bring in the domain, as the physiological respective roles of the two subtypes of melatonin receptors, is still poorly understood. Poly-pharmacology applications and multitarget ligands have also been considered.
Collapse
MESH Headings
- Ligands
- Humans
- Animals
- Receptor, Melatonin, MT2/metabolism
- Receptor, Melatonin, MT2/agonists
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT1/agonists
- Receptor, Melatonin, MT1/antagonists & inhibitors
- Receptors, Melatonin/metabolism
- Receptors, Melatonin/agonists
- Melatonin/metabolism
- History, 20th Century
Collapse
Affiliation(s)
- Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| | - Jean A Boutin
- Laboratory of Neuroendocrine Endocrine and Germinal Differentiation and Communication (NorDiC), Univ Rouen Normandie, Inserm, NorDiC, Rouen, France
| | | | - Darius P Zlotos
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Egypt
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| |
Collapse
|
2
|
Costello HM, Johnston JG, Juffre A, Crislip GR, Gumz ML. Circadian clocks of the kidney: function, mechanism, and regulation. Physiol Rev 2022; 102:1669-1701. [PMID: 35575250 PMCID: PMC9273266 DOI: 10.1152/physrev.00045.2021] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 05/03/2022] [Accepted: 05/07/2022] [Indexed: 11/22/2022] Open
Abstract
An intrinsic cellular circadian clock is located in nearly every cell of the body. The peripheral circadian clocks within the cells of the kidney contribute to the regulation of a variety of renal processes. In this review, we summarize what is currently known regarding the function, mechanism, and regulation of kidney clocks. Additionally, the effect of extrarenal physiological processes, such as endocrine and neuronal signals, on kidney function is also reviewed. Circadian rhythms in renal function are an integral part of kidney physiology, underscoring the importance of considering time of day as a key biological variable. The field of circadian renal physiology is of tremendous relevance, but with limited physiological and mechanistic information on the kidney clocks this is an area in need of extensive investigation.
Collapse
Affiliation(s)
- Hannah M Costello
- Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida
- Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, Florida
| | - Jermaine G Johnston
- Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, Florida
- North Florida/South Georgia Malcom Randall Department of Veterans Affairs Medical Center, Gainesville, Florida
| | - Alexandria Juffre
- Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida
- Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, Florida
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida
| | - G Ryan Crislip
- Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida
- Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, Florida
| | - Michelle L Gumz
- Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida
- Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida, Gainesville, Florida
- North Florida/South Georgia Malcom Randall Department of Veterans Affairs Medical Center, Gainesville, Florida
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida
- Center for Integrative Cardiovascular and Metabolic Diseases, University of Florida, Gainesville, Florida
| |
Collapse
|
3
|
Bonnaud A, Dupré C, Legros C, Boutin JA. MT1 Receptor Signaling Pathways by Impedance Measurement. Methods Mol Biol 2022; 2550:201-206. [PMID: 36180694 DOI: 10.1007/978-1-0716-2593-4_25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Melatonin exerts its classical effects of relay of the circadian rhythm through two G protein-coupled receptors, MT1 and MT2. The functions attributed to melatonin are so numerous that the action of this neurohormone should be through several protein targets or through new coupled biochemistry routes at its receptors. In order to better explore and understand these melatonin-dependent activities, we enlarged the functional pathways linked to the activation of the receptors in living system. Impedance has been shown to rely on the shape-shifting capacity of receptor-associated mechanisms. Those changes elicited by an agonist lead to changes in the actual shape of the cells, and thus to their electric conductivity. The impact of those changes onto the physiology of the cells is not completely understood from a mechanistic point of view, but the measure of these changes associated with various ligands at the melatonin receptor(s) might bring new information on melatonin-dependent cell reactivity. The following chapter is a detailed account of the way impedance can be measured in MT1-experssing cells.
Collapse
Affiliation(s)
- Anne Bonnaud
- Pole d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Clémence Dupré
- Pole d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Céline Legros
- Pole d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
- Eurofins Discovery, Celle l'Evescault, France
| | - Jean A Boutin
- Pole d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France.
- PHARMADEV (Pharmacochimie et biologie pour le développement), Faculté de Pharmacie, Toulouse, France.
| |
Collapse
|
4
|
Gautier C, Theret I, Lizzo G, Ferry G, Guénin SP, Boutin JA. Why Are We Still Cloning Melatonin Receptors? A Commentary. Methods Mol Biol 2022; 2550:267-281. [PMID: 36180698 DOI: 10.1007/978-1-0716-2593-4_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Cloning may seem to be a view from the past. The time before software, computers and AI were invented. It seems to us worth discussing these points in view of our favorite target: the melatoninergic system. In a few stances, it might be important to point out that even in the new era of dry science, there is still a need to experiment and to prove at the bench that our in silico assertions are right. Most of the living animals express to some extend the melatonin receptors. Some of these animal genomes were completely or partially sequenced, and it is tempting to extract from this huge information the sequence(s) of our favorite genes (MLT receptors). Then, why bother cloning, as opposed to simply built the gene and express it in a host cell? Because the genetic boundaries of the expressed sequence(s) are not 100% sure. Because the melatonin receptor gene(s) comprise a first exon 25,000 base pair far from the second one and the limits between this Ex1 and In1-as between In1 and Ex2-are subject to changes that might have a huge impact on the biochemical properties of the receptor, once expressed. Because a receptor is a biochemical entity with characteristics that are important for the functioning of this particular pathway, and more generally, for the functioning of life.
Collapse
Affiliation(s)
- Célia Gautier
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Isabelle Theret
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Giulia Lizzo
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Gilles Ferry
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Sophie-Pénélope Guénin
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Jean A Boutin
- Pôle d'expertise Biotechnologie, Chimie & Biologie, Institut de Recherches Servier, Croissy-sur-Seine, France.
- Pharma-Dev (Pharmacochimie et Biologie pour le Développement), Faculté de Pharmacie, UMR 152, Université de Toulouse, Toulouse, France.
| |
Collapse
|
5
|
Shabajee-Alibay P, Bonnaud A, Malpaux B, Delagrange P, Audinot V, Yous S, Boutin JA, Stephan JP, Leprince J, Legros C. A putative new melatonin binding site in sheep brain, MTx: preliminary observations and characteristics. J Pharmacol Exp Ther 2021; 380:JPET-AR-2021-000785. [PMID: 34706966 DOI: 10.1124/jpet.121.000785] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 09/29/2021] [Accepted: 10/22/2021] [Indexed: 11/22/2022] Open
Abstract
In mammals, MT1 and MT2 melatonin receptors are high affinity G protein-coupled receptors and are thought to be involved in the integration of the melatonin signaling throughout the brain and periphery. In the present study, we describe a new melatonin binding site, named MTx, with a peculiar pharmacological profile. This site had a low affinity for 2-[125I]-melatonin in saturation assays in hypothalamus and retina (pKD = 9.13 {plus minus} 0.05, Bmax = 1.12 {plus minus} 0.11 fmol/mg protein and pKD = 8.81 {plus minus} 0.50, Bmax = 7.65 {plus minus} 2.64 fmol/mg protein, respectively) and a very high affinity, in competition assays, for melatonin (pKi = 13.08 {plus minus} 0.18), and other endogenous compounds. Using autoradiography, we showed a preferential localization of the MTx in periventricular areas of the sheep brain, with a density 3 to 8 times higher than those observed for ovine MT1 In addition, using a set of well-characterized ligands, we showed that this site did not correspond to any of the following receptors: MT1, MT2, MT3 , D1, D2, noradrenergic, nor 5-HT2 Based on its affinity for melatonin, MTx did not seem to be implicated in the integration of cerebral melatonin concentration variations since they were saturating for MTx. Nevertheless, it remained of prime importance because of its periventricular distribution, in close contact with the CSF, and its peculiar pharmacological profile responding to both melatoninergic and serotoninergic compounds. Significance Statement Herein a putative new melatonin binding site is described in sheep brain parts in close contact with the 3rd ventricle. The characteristics of the pharmacological profile of this site is different from anything previously reported in the literature. The present work forms the basis of future full pharmacological characterization.
Collapse
Affiliation(s)
- Preety Shabajee-Alibay
- Laboratoire de Différenciation et Communication Neuronale et Neuroendocrine, Normandie Université, UNIROUEN, INSERM 1239, France
| | | | - Benoit Malpaux
- UMR Physiologie de la Reproduction et des Comportements, INRA Val de Loire, France
| | | | | | - Said Yous
- UMR-S 1172-LiNC-Lille Neuroscience & Cognition, Univ. Lille, INSERM, CHU Lille, France
| | - Jean A Boutin
- Institut de Recherches Internationales Servier, France
| | | | - Jérôme Leprince
- Laboratoire de Différenciation et Communication Neuronale et Neuroendocrine, Normandie Université, UNIROUEN, INSERM 1239, France
| | | |
Collapse
|
6
|
Ramirez AVG, Filho DR, de Sá LBPC. Melatonin and its Relationships with Diabetes and Obesity: A Literature Review. Curr Diabetes Rev 2021; 17:e072620184137. [PMID: 32718296 DOI: 10.2174/1573399816666200727102357] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 07/13/2020] [Accepted: 07/15/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Obesity is an important clinical entity, causing many public health issues. Around two billion people in the world are overweight and obese. Almost 40% of American adults are obese and Brazil has about 18 million obese people. Nowadays, 415 million people have diabetes, around 1 in every 11 adults. These numbers will rise to 650 million people within 20 years. Melatonin shows a positive profile on the regulation of the metabolism of the human body. OBJECTIVE This study aimed to carry out a broad narrative review of the metabolic profile and associations between melatonin, diabetes and obesity. METHODS Article reviews, systematic reviews, prospective studies, retrospective studies, randomized, double-blind, and placebo-controlled trials in humans recently published were selected and analyzed. A total of 368 articles were collated and submitted to the eligibility analysis. Subsequently, 215 studies were selected to compose the content part of the paper, and 153 studies composed the narrative review. RESULTS Studies suggest a possible role of melatonin in metabolic diseases such as obesity, T2DM and metabolic syndrome. Intervention studies using this hormone in metabolic diseases are still unclear regarding the possible benefit of it. There is so far no consensus about the possible role of melatonin as an adjuvant in the treatment of metabolic diseases. More studies are necessary to define possible risks and benefits of melatonin as a therapeutic agent.
Collapse
Affiliation(s)
- Ana V G Ramirez
- Clinic Ana Valeria (CAV)- Clinic of Nutrition and Health Science, Street Antônio José Martins Filho, 300, Sao Jose do Rio Preto SP, 15092-230, Brazil
| | - Durval R Filho
- Associacao Brasileira de Nutrologia (ABRAN)/Brazilian Association of Nutrology, Catanduva/SP, Rua Belo Horizonte, 909 - Centro, Catanduva SP, Brazil
| | | |
Collapse
|
7
|
Legros C, Dupré C, Brasseur C, Bonnaud A, Bruno O, Valour D, Shabajee P, Giganti A, Nosjean O, Kenakin TP, Boutin JA. Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT 1 and MT 2 receptors. Pharmacol Res Perspect 2020; 8:e00539. [PMID: 31893123 PMCID: PMC6935685 DOI: 10.1002/prp2.539] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 09/30/2019] [Accepted: 10/10/2019] [Indexed: 12/20/2022] Open
Abstract
Melatonin is a neurohormone that translates the circadian rhythm to the peripheral organs through a series of binding sites identified as G protein-coupled receptors MT1 and MT2. Due to minute amounts of receptor proteins in target organs, the main tool of studies of the melatoninergic system is recombinant expression of the receptors in cellular hosts. Although a number of studies exist on these receptors, studies of several signaling pathways using a large number of melatoninergic compounds are rather limited. We chose to fill this gap to better describe a panel of compounds that have been only partially characterized in terms of functionality. First, we characterized HEK cells expressing MT1 or MT2, and several signaling routes with melatonin itself to validate the approach: GTPγS, cAMP production, internalization, β-arrestin recruitment, and cell morphology changes (CellKey ® ). Second, we chose 21 compounds from our large melatoninergic chemical library and characterized them using this panel of signaling pathways. Notably, antagonists were infrequent, and their functionality depended largely on the pathway studied. This will permit redefining the availability of molecular tools that can be used to better understand the in situ activity and roles of these receptors.
Collapse
Affiliation(s)
- Céline Legros
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Clémence Dupré
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Chantal Brasseur
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Anne Bonnaud
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Olivier Bruno
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Damien Valour
- Pôle d’Expetise Méthodologie et Valorisation des DonnéesInstitut de Recherches Internationales ServierSuresnesFrance
| | - Preety Shabajee
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Adeline Giganti
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
| | - Olivier Nosjean
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
- Present address:
Institut de Recherches Internationales SERVIERSuresnesFrance
| | - Terrence P. Kenakin
- Department of PharmacologyUniversity of North Carolina School of MedicineChapel HillNCUSA
| | - Jean A. Boutin
- Pôle d’Expertise BiotechnologieChimie & BiologieInstitut de Recherches ServierCroissy‐sur‐SeineFrance
- Present address:
Institut de Recherches Internationales SERVIERSuresnesFrance
| |
Collapse
|
8
|
Mok JX, Ooi JH, Ng KY, Koh RY, Chye SM. A new prospective on the role of melatonin in diabetes and its complications. Horm Mol Biol Clin Investig 2019; 40:/j/hmbci.ahead-of-print/hmbci-2019-0036/hmbci-2019-0036.xml. [PMID: 31693492 DOI: 10.1515/hmbci-2019-0036] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Accepted: 10/01/2019] [Indexed: 01/01/2023]
Abstract
Melatonin is a hormone secreted by the pineal gland under the control of the circadian rhythm, and is released in the dark and suppressed during the day. In the past decades, melatonin has been considered to be used in the treatment for diabetes mellitus (DM). This is due to a functional inter-relationship between melatonin and insulin. Elevated oxidative stress is a feature found in DM associated with diabetic neuropathy (DN), retinopathy (DR), nephropathy and cardiovascular disease. Reactive oxygen species (ROS) and nitrogen oxidative species (NOS) are usually produced in massive amounts via glucose and lipid peroxidation, and this leads to diabetic complications. At the molecular level, ROS causes damage to the biomolecules and triggers apoptosis. Melatonin, as an antioxidant and a free radical scavenger, ameliorates oxidative stress caused by ROS and NOS. Besides that, melatonin administration is proven to bring other anti-DM effects such as reducing cellular apoptosis and promoting the production of antioxidants.
Collapse
Affiliation(s)
- Jia Xin Mok
- School of Medical Laboratory Science, University of Otago, Dunedin 9054, New Zealand.,University of Otago, Dunedin School of Medicine, Department of Pathology, Medical Laboratory Science, Dunedin 9016, New Zealand
| | - Jack Hau Ooi
- International Medical University, School of Health Science, Kuala Lumpur 57000, Malaysia
| | - Khuen Yen Ng
- Monash University Malaysia, School of Pharmacy, Selangor 47500, Malaysia
| | - Rhun Yian Koh
- International Medical University, School of Health Science, Kuala Lumpur 57000, Malaysia
| | - Soi Moi Chye
- International Medical University, School of Health Science, Kuala Lumpur 57000, Malaysia.,School of Health Science, Division of Biomedical Science and Biotechnology, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia, Phone: +60-3-27317220, Fax: +06-3-86567229
| |
Collapse
|
9
|
Cecon E, Ivanova A, Luka M, Gbahou F, Friederich A, Guillaume JL, Keller P, Knoch K, Ahmad R, Delagrange P, Solimena M, Jockers R. Detection of recombinant and endogenous mouse melatonin receptors by monoclonal antibodies targeting the C-terminal domain. J Pineal Res 2019; 66:e12540. [PMID: 30475390 DOI: 10.1111/jpi.12540] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 11/04/2018] [Accepted: 11/16/2018] [Indexed: 02/06/2023]
Abstract
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non-24-hour sleep-wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2 , belonging to the G protein-coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2 . Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2 . None of the mABs cross-reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR-KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta-cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies.
Collapse
Affiliation(s)
- Erika Cecon
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| | - Anna Ivanova
- Molecular Diabetology, Faculty of Medicine, University Hospital, TU Dresden, Dresden, Germany
- Faculty of Medicine, Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich Neuherberg, Germany
| | - Marine Luka
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| | - Florence Gbahou
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| | - Anne Friederich
- Molecular Diabetology, Faculty of Medicine, University Hospital, TU Dresden, Dresden, Germany
- Faculty of Medicine, Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich Neuherberg, Germany
| | - Jean-Luc Guillaume
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| | - Patrick Keller
- Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany
| | - Klaus Knoch
- Molecular Diabetology, Faculty of Medicine, University Hospital, TU Dresden, Dresden, Germany
- Faculty of Medicine, Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich Neuherberg, Germany
| | - Raise Ahmad
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| | - Philippe Delagrange
- Pôle d'Innovation Thérapeutique Neuropsychiatrie, Institut de Recherches Servier, Croissy, France
| | - Michele Solimena
- Molecular Diabetology, Faculty of Medicine, University Hospital, TU Dresden, Dresden, Germany
- Faculty of Medicine, Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich Neuherberg, Germany
- Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany
| | - Ralf Jockers
- Inserm U1016, Institut Cochin, Paris, France
- CNRS UMR 8104, Paris, France
- Sorbonne Paris Cité, Univ. Paris Descartes, Paris, France
| |
Collapse
|
10
|
Gautier C, Dufour E, Dupré C, Lizzo G, Caignard S, Riest-Fery I, Brasseur C, Legros C, Delagrange P, Nosjean O, Simonneaux V, Boutin JA, Guenin SP. Hamster Melatonin Receptors: Cloning and Binding Characterization of MT₁ and Attempt to Clone MT₂. Int J Mol Sci 2018; 19:E1957. [PMID: 29973510 PMCID: PMC6073278 DOI: 10.3390/ijms19071957] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 06/27/2018] [Accepted: 07/02/2018] [Indexed: 12/17/2022] Open
Abstract
For many years, it was of interest to identify the sequences encoding the two melatonin receptors (MT₁ and MT₂) from various species. After publishing the basic molecular characterization of the human, rat, mouse, sheep, and platypus MT₁, MT₂, or Mel1c receptors, we began cloning the genes from other animals, such as birds, bats, and vipers. The goal was to advance the receptor crystallization, which could greatly contribute the understanding of the sequence/stability relationship. European hamster MT₁ receptor was cloned for the first time from this gender, was expressed in stable form in cells, and its binding characterized with a sample of 19 melatonin ligands. Siberian hamster (Phodopus sungorus) expresses a non-functional MT₂. We observed that unlike this hamster, the European hamster (Cricetus cricetus) does not have a stop codon in the MT₂ sequence. Thus, we undertook the tedious task of cloning the MT₂ receptor. We partially succeeded, sequencing the complete exon 2 and a fragment of exon 1 (from putative amino acids 12 to 38 and 77 to 323), after several years of efforts. In order to show that the protein parts we cloned were capable to sustain some binding capacities, we designed a chimeric MT₂ receptor using a consensus sequence to replace the unknown amino acids, based on other small rodent MT₂ sequences. This chimeric construct could bind melatonin in the nanomolar range. This work is meant to be the basis for attempts from other laboratories of the community to determine the complete natural sequence of the European hamster MT₂ receptor. The present work is the first to show that, among the hamsters, if the Siberian is a natural knockout for MT₂, the European one is not.
Collapse
Affiliation(s)
- Célia Gautier
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
- Institut des Neurosciences Cellulaires et Intégratives, 67084 Strasbourg, France.
| | - Emilie Dufour
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Clémence Dupré
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Giulia Lizzo
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Sarah Caignard
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Isabelle Riest-Fery
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Chantal Brasseur
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Céline Legros
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Philippe Delagrange
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| | - Olivier Nosjean
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
- Institut de Recherches Internationales Servier, 92150 Suresnes, France.
| | - Valérie Simonneaux
- Institut des Neurosciences Cellulaires et Intégratives, 67084 Strasbourg, France.
| | - Jean A Boutin
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
- Institut de Recherches Internationales Servier, 92150 Suresnes, France.
| | - Sophie-Pénélope Guenin
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, 78290 Croissy sur Seine, France.
| |
Collapse
|
11
|
Gautier C, Guenin SP, Riest-Fery I, Perry TJ, Legros C, Nosjean O, Simonneaux V, Grützner F, Boutin JA. Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). PLoS One 2018. [PMID: 29529033 PMCID: PMC5846726 DOI: 10.1371/journal.pone.0191904] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Melatonin is a neurohormone produced in both animals and plants. It binds at least three G-protein-coupled receptors: MT1 and MT2, and Mel1cGPR. Mammalian GPR50 evolved from the reptilian/avian Mel1c and lost its capacity to bind melatonin in all the therian mammal species that have been tested. In order to determine if binding is lost in the oldest surviving mammalian lineage of monotremes we investigated whether the melatonin receptor has the ability to bind melatonin in the platypus (Ornithorhynchus anatinus), and evaluated its pharmacological profile. Sequence and phylogenetic analysis showed that platypus has in fact retained the ancestral Mel1c and has the capacity to bind melatonin similar to other mammalian melatonin receptors (MT1 and MT2), with an affinity in the 1 nM range. We also investigated the binding of a set of melatoninergic ligands used previously to characterize the molecular pharmacology of the melatonin receptors from sheep, rats, mice, and humans and found that the general profiles of these compounds make Mel1c resemble human MT1 more than MT2. This work shows that the loss of GPR50 binding evolved after the divergence of monotremes less than 190MYA in therian mammals.
Collapse
MESH Headings
- Animals
- Base Sequence
- COS Cells
- Chlorocebus aethiops
- Cloning, Molecular/methods
- Melatonin/metabolism
- Phylogeny
- Platypus/genetics
- Platypus/metabolism
- Protein Binding
- Receptor, Melatonin, MT1/chemistry
- Receptor, Melatonin, MT1/genetics
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT2/chemistry
- Receptor, Melatonin, MT2/genetics
- Receptor, Melatonin, MT2/metabolism
- Receptors, Melatonin/chemistry
- Receptors, Melatonin/genetics
- Receptors, Melatonin/metabolism
Collapse
Affiliation(s)
- Célia Gautier
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
- Institut des Neurosciences Cellulaires et Intégratives, Strasbourg, France
| | - Sophie-Penelope Guenin
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
| | - Isabelle Riest-Fery
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
| | - Tahlia Jade Perry
- School of Biological Sciences, The University of Adelaide, Adelaide, Australia
| | - Céline Legros
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
| | - Olivier Nosjean
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Valerie Simonneaux
- Institut des Neurosciences Cellulaires et Intégratives, Strasbourg, France
| | - Frank Grützner
- School of Biological Sciences, The University of Adelaide, Adelaide, Australia
| | - Jean A. Boutin
- PEX Biotechnologie Chimie & Biologie, Institut de Recherches Servier, Croissy sur Seine, France
- Institut de Recherches Internationales Servier, Suresnes, France
- * E-mail:
| |
Collapse
|
12
|
Huang CY, Kuo CW, Kavala V, Yao CF. Syntheses of 2-Benzylbenzofuran Derivatives and 2-Aryl-nitrochroman Derivatives from Nitroalkene Precursors. European J Org Chem 2016. [DOI: 10.1002/ejoc.201600314] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
13
|
Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. J Pharmacol Exp Ther 2016; 356:681-92. [PMID: 26759496 DOI: 10.1124/jpet.115.229989] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 01/11/2016] [Indexed: 12/15/2022] Open
Abstract
Melatonin exerts a variety of physiologic activities that are mainly relayed through the melatonin receptors MT1 and MT2 Low expressions of these receptors in tissues have led to widespread experimental use of the agonist 2-[(125)I]-iodomelatonin as a substitute for melatonin. We describe three iodinated ligands: 2-(2-[(2-iodo-4,5-dimethoxyphenyl)methyl]-4,5-dimethoxy phenyl) (DIV880) and (2-iodo-N-2-[5-methoxy-2-(naphthalen-1-yl)-1H-pyrrolo[3,2-b]pyridine-3-yl])acetamide (S70254), which are specific ligands at MT2 receptors, and N-[2-(5-methoxy-1H-indol-3-yl)ethyl]iodoacetamide (SD6), an analog of 2-[(125)I]-iodomelatonin with slightly different characteristics. Here, we further characterized these new ligands with regards to their molecular pharmacology. We performed binding experiments, saturation assays, association/dissociation rate measurements, and autoradiography using sheep and rat tissues and recombinant cell lines. Our results showed that [(125)I]-S70254 is receptor, and can be used with both cells and tissue. This radioligand can be used in autoradiography. Similarly, DIV880, a partial agonist [43% of melatonin on guanosine 5'-3-O-(thio)triphosphate binding assay], selective for MT2, can be used as a tool to selectively describe the pharmacology of this receptor in tissue samples. The molecular pharmacology of both human melatonin receptors MT1 and MT2, using a series of 24 ligands at these receptors and the new radioligands, did not lead to noticeable variations in the profiles. For the first time, we described radiolabeled tools that are specific for one of the melatonin receptors (MT2). These tools are amenable to binding experiments and to autoradiography using sheep or rat tissues. These specific tools will permit better understanding of the role and implication in physiopathologic processes of the melatonin receptors.
Collapse
Affiliation(s)
- Céline Legros
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Chantal Brasseur
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Philippe Delagrange
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Pierre Ducrot
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Olivier Nosjean
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| | - Jean A Boutin
- Pôle d'Expertise Biotechnologie, Chimie, Biologie (C.L., C.B., P.Du., O.N., J.A.B.), and Unité de Recherches et Découvertes en Neurosciences (P.De.), Institut de Recherches SERVIER, Croissy-sur-Seine, France
| |
Collapse
|
14
|
Cordeiro N, Wijkhuisen A, Savatier A, Moulharat N, Ferry G, Léonetti M. Obtaining anti-type 1 melatonin receptor antibodies by immunization with melatonin receptor-expressing cells. J Immunol Methods 2015; 428:37-41. [PMID: 26657944 DOI: 10.1016/j.jim.2015.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Revised: 11/25/2015] [Accepted: 11/30/2015] [Indexed: 11/25/2022]
Abstract
Antibodies (Abs) specific to cell-surface receptors are attractive tools for studying the physiological role of such receptors or for controlling their activity. We sought to obtain such antibodies against the type 1 receptor for melatonin (MT1). For this, we injected mice with CHO cells transfected with a plasmid encoding human MT1 (CHO-MT1-h), in the presence or absence of an adjuvant mixture containing Alum and CpG1018. As we previously observed that the immune response to a protein antigen is increased when it is coupled to a fusion protein, called ZZTat101, we also investigated if the association of ZZTat101 with CHO-MT1-h cells provides an immunogenic advantage. We measured similar levels of anti-CHO and anti-MT1-h Ab responses in animals injected with either CHO-MT1-h cells or ZZTat101/CHO-MT1-h cells, with or without adjuvant, indicating that neither the adjuvant mixture nor ZZTat101 increased the anti-cell immune response. Then, we investigated whether the antisera also recognized murine MT1 (MT1-m). Using cloned CHO cells transfected with a plasmid encoding MT1-m, we found that antisera raised against CHO-MT1-h cells also bound the mouse receptor. Altogether our studies indicate that immunizing approaches based on MT1-h-expressing CHO cells allow the production of polyclonal antibodies against MT1 receptors of different origins. This paves the way to preparation of MT1-specific monoclonal antibodies.
Collapse
Affiliation(s)
- Nelia Cordeiro
- CEA, institut de Biologie et de Technologie de Saclay (iBiTec-S), Service de Pharmacologie et d'immunoanalyse (SPI), 91191 Gif sur Yvette, France
| | | | - Alexandra Savatier
- CEA, institut de Biologie et de Technologie de Saclay (iBiTec-S), Service de Pharmacologie et d'immunoanalyse (SPI), 91191 Gif sur Yvette, France
| | - Natacha Moulharat
- Institut de Recherches Servier, Division Biotechnologie, Pharmacologie Moléculaire et Cellulaire, 125 Chemin de Ronde, 78290 Croissy-Sur-Seine, France
| | - Gilles Ferry
- Institut de Recherches Servier, Division Biotechnologie, Pharmacologie Moléculaire et Cellulaire, 125 Chemin de Ronde, 78290 Croissy-Sur-Seine, France
| | - Michel Léonetti
- CEA, institut de Biologie et de Technologie de Saclay (iBiTec-S), Service de Pharmacologie et d'immunoanalyse (SPI), 91191 Gif sur Yvette, France.
| |
Collapse
|
15
|
Boutin JA. Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opin Ther Targets 2015; 20:303-17. [DOI: 10.1517/14728222.2016.1091882] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Jean A Boutin
- Institut de Recherches SERVIER, Pole d’Expertise Biotechnologie, Chimie & Biologie, 125, chemin de Ronde, 78290 Croissy-sur-Seine, France
| |
Collapse
|
16
|
Abstract
Melatonin (N-acetyl-5-methoxytryptamine, MLT) is a neuroendocrine hormone, which is primarily synthesized by the pineal gland in vertebrates. Melatonin is a remarkable molecule with diverse biological and physiological actions and is involved in the regulation of various important functions such as circadian rhythm, energy metabolism, the reproductive system, the cardiovascular system, and the neuropsychiatric system. It also plays a role in disease by having anti-neoplastic and anti-osteoarthritic effects among others. Recently, research has focused on the roles of melatonin in oxidative stress, lipid metabolism, and hepatic steatosis and its potential therapeutic roles.
Collapse
Affiliation(s)
- Hang Sun
- Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China
| | - Fang-fang Huang
- Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China
| | - Shen Qu
- Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
| |
Collapse
|
17
|
Tosini G, Owino S, Guillaume JL, Jockers R. Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. Bioessays 2014; 36:778-87. [PMID: 24903552 PMCID: PMC4151498 DOI: 10.1002/bies.201400017] [Citation(s) in RCA: 82] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Melatonin, the neuro-hormone synthesized during the night, has recently seen an unexpected extension of its functional implications toward type 2 diabetes development, visual functions, sleep disturbances, and depression. Transgenic mouse models were instrumental for the establishment of the link between melatonin and these major human diseases. Most of the actions of melatonin are mediated by two types of G protein-coupled receptors, named MT1 and MT2 , which are expressed in many different organs and tissues. Understanding the pharmacology and function of mouse MT1 and MT2 receptors, including MT1 /MT2 heteromers, will be of crucial importance to evaluate the relevance of these mouse models for future therapeutic developments. This review will critically discuss these aspects, and give some perspectives including the generation of new mouse models.
Collapse
Affiliation(s)
- Gianluca Tosini
- Neuroscience Institute and Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, GA, USA
| | | | | | | |
Collapse
|
18
|
Logez C, Berger S, Legros C, Banères JL, Cohen W, Delagrange P, Nosjean O, Boutin JA, Ferry G, Simonin F, Wagner R. Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes. PLoS One 2014; 9:e100616. [PMID: 24959712 PMCID: PMC4069108 DOI: 10.1371/journal.pone.0100616] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Accepted: 05/27/2014] [Indexed: 01/08/2023] Open
Abstract
The human melatonin MT1 receptor—belonging to the large family of G protein-coupled receptors (GPCRs)—plays a key role in circadian rhythm regulation and is notably involved in sleep disorders and depression. Structural and functional information at the molecular level are highly desired for fine characterization of this receptor; however, adequate techniques for isolating soluble MT1 material suitable for biochemical and biophysical studies remain lacking. Here we describe the evaluation of a panel of constructs and host systems for the production of recombinant human MT1 receptors, and the screening of different conditions for their solubilization and purification. Our findings resulted in the establishment of an original strategy using a mixture of Fos14 and CHAPS detergents to extract and purify a recombinant human MT1 from Pichia pastoris membranes. This procedure enabled the recovery of relatively pure, monomeric and ligand-binding active MT1 receptor in the near-milligram range. A comparative study based on extensive ligand-binding characterization highlighted a very close correlation between the pharmacological profiles of MT1 purified from yeast and the same receptor present in mammalian cell membranes. The high quality of the purified MT1 was further confirmed by its ability to activate its cognate Gαi protein partner when reconstituted in lipid discs, thus opening novel paths to investigate this receptor by biochemical and biophysical approaches.
Collapse
Affiliation(s)
- Christel Logez
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Sylvie Berger
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Céline Legros
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Jean-Louis Banères
- CNRS UMR 5247, Institut des Biomolécules Max Mousseron (IBMM), Université de Montpellier 1 and Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - William Cohen
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Philippe Delagrange
- Unité de Recherches et Découvertes en Neurosciences, Institut de Recherche Servier, Croissy-sur-Seine, France
| | - Olivier Nosjean
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Jean A. Boutin
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
- * E-mail:
| | - Gilles Ferry
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, Croissy-sur-Seine, France
| | - Frédéric Simonin
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
| | - Renaud Wagner
- CNRS UMR7242/Laboratoire d'excellence MEDALIS, Institut de Recherche de l'ESBS, Biotechnologie et Signalisation Cellulaire, Université de Strasbourg, Illkirch, France
| |
Collapse
|
19
|
Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, Boutin JA, Nosjean O. Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol 2014; 171:186-201. [PMID: 24117008 PMCID: PMC3874706 DOI: 10.1111/bph.12457] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 09/13/2013] [Accepted: 09/18/2013] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE Melatonin receptors have been extensively characterized regarding their affinity and pharmacology, mostly using 2-[(125)I]-melatonin as a radioligand. Although [(3)H]-melatonin has the advantage of corresponding to the endogenous ligand of the receptor, its binding has not been well described. EXPERIMENTAL APPROACH We characterized [(3)H]-melatonin binding to the hMT₁ and hMT₂ receptors expressed in a range of cell lines and obtained new insights into the molecular pharmacology of melatonin receptors. KEY RESULTS The binding of [(3)H]-melatonin to the hMT₁ and hMT₂ receptors displayed two sites on the saturation curves. These two binding sites were observed on cell membranes expressing recombinant receptors from various species as well as on whole cells. Furthermore, our GTPγS/NaCl results suggest that these sites on the saturation curves correspond to the G-protein coupled and uncoupled states of the receptors, whose pharmacology was extensively characterized. CONCLUSIONS AND IMPLICATIONS hMT₁ and hMT₂ receptors spontaneously exist in two states when expressed in cell lines; these states can be probed by [(3)H]-melatonin binding. Overall, our results suggest that physiological regulation of the melatonin receptors may result from complex and subtle mechanisms, a small difference in affinity between the active and inactive states of the receptor, and spontaneous coupling to G-proteins.
Collapse
Affiliation(s)
- Céline Legros
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Séverine Devavry
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
- INRA, UMR85 Physiologie de la Reproduction et des ComportementsNouzilly, France
- CNRS, UMR6175Nouzilly, France
| | - Sarah Caignard
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Clémence Tessier
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Philippe Delagrange
- Unité de Recherches en Neurosciences, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Christine Ouvry
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Jean A Boutin
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| | - Olivier Nosjean
- Biotechnologies, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches ServierCroissy-sur-Seine, France
| |
Collapse
|
20
|
Legros C, Matthey U, Grelak T, Pedragona-Moreau S, Hassler W, Yous S, Thomas E, Suzenet F, Folleas B, Lefoulon F, Berthelot P, Caignard DH, Guillaumet G, Delagrange P, Brayer JL, Nosjean O, Boutin JA. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci 2013; 14:8948-62. [PMID: 23698757 PMCID: PMC3676766 DOI: 10.3390/ijms14058948] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2013] [Revised: 04/14/2013] [Accepted: 04/15/2013] [Indexed: 12/15/2022] Open
Abstract
Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[125I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including the discovery of agonists and antagonists for the receptors and minute details about their molecular behavior. Recently, we attempted to expand the panel of radioligands available for studying the melatonin receptors by using the newly discovered compounds SD6, DIV880, and S70254. These compounds were characterized for their affinities to the hMT1 and hMT2 recombinant receptors and their functionality in the classical GTPS system. SD6 is a full agonist, equilibrated between the receptor isoforms, whereas S70254 and DIV880 are only partial MT2 agonists, with Ki in the low nanomolar range while they have no affinity to MT1 receptors. These new tools will hopefully allow for additions to the current body of information on the native localization of the receptor isoforms in tissues.
Collapse
Affiliation(s)
- Céline Legros
- BPMC, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: (C.L.); (O.N.)
| | - Ulrich Matthey
- Celerion Switzerland AG Allmendstrasse 32, Fehraltorf CH-8320, Switzerland; E-Mails: (U.M.); (T.G.)
| | - Teresa Grelak
- Celerion Switzerland AG Allmendstrasse 32, Fehraltorf CH-8320, Switzerland; E-Mails: (U.M.); (T.G.)
| | | | - Werner Hassler
- ANAWA Trading SA, Unterdorfstrasse 21, Wangen CH-8602, Switzerland; E-Mail:
| | - Saïd Yous
- Université Lille Nord de France, F-59000 Lille, France & UDSL, EA GRIIOT, UFR Pharmacie, Lille F-59000, France; E-Mail: (S.Y.); (P.B.)
| | - Emmanuel Thomas
- DIVERCHIM, 6 Rue du Noyer, Roissy 95700, France; E-Mails: (E.T.); (B.F.); (J.-L.B.)
| | - Franck Suzenet
- Institut de Chimie Organique et Analytique, UMR CNRS 7311, Université d’Orléans, rue de Chartres, Orléans 45067, France; E-Mails: (F.S.); (G.G.)
| | - Benoît Folleas
- DIVERCHIM, 6 Rue du Noyer, Roissy 95700, France; E-Mails: (E.T.); (B.F.); (J.-L.B.)
| | - François Lefoulon
- Technologie SERVIER, 27 rue Vignat, Orléans 45000, France; E-Mails: (S.P.-M.); (F.L.)
| | - Pascal Berthelot
- Université Lille Nord de France, F-59000 Lille, France & UDSL, EA GRIIOT, UFR Pharmacie, Lille F-59000, France; E-Mail: (S.Y.); (P.B.)
| | - Daniel-Henri Caignard
- Unité de Recherches et Découvertes en Neurosciences, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: (D.-H.C.); (P.D.)
| | - Gérald Guillaumet
- Institut de Chimie Organique et Analytique, UMR CNRS 7311, Université d’Orléans, rue de Chartres, Orléans 45067, France; E-Mails: (F.S.); (G.G.)
| | - Philippe Delagrange
- Unité de Recherches et Découvertes en Neurosciences, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: (D.-H.C.); (P.D.)
| | - Jean-Louis Brayer
- DIVERCHIM, 6 Rue du Noyer, Roissy 95700, France; E-Mails: (E.T.); (B.F.); (J.-L.B.)
| | - Olivier Nosjean
- BPMC, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: (C.L.); (O.N.)
| | - Jean A. Boutin
- BPMC, Institut de Recherches SERVIER, 125 chemin de Ronde, Croissy-sur-Seine 78290, France; E-Mails: (C.L.); (O.N.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-0155-722-748; Fax: +33-0155-722-810
| |
Collapse
|
21
|
Adamczyk-Sowa M, Sowa P, Zwirska-Korczala K, Pierzchala K, Bartosz G, Sadowska-Bartosz I. Role of melatonin receptor MT2and quinone reductase II in the regulation of the redox status of 3T3-L1 preadipocytes in vitro. Cell Biol Int 2013; 37:835-42. [DOI: 10.1002/cbin.10105] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2013] [Accepted: 03/21/2013] [Indexed: 12/11/2022]
Affiliation(s)
- Monika Adamczyk-Sowa
- Department of Neurology in Zabrze; Medical University of Silesia; ul. 3-go Maja 13-15; Zabrze; 41-800; Poland
| | - Pawel Sowa
- ENT Department in Zabrze; Medical University of Silesia; Silesia; Poland
| | | | - Krystyna Pierzchala
- Department of Neurology in Zabrze; Medical University of Silesia; ul. 3-go Maja 13-15; Zabrze; 41-800; Poland
| | | | - Izabela Sadowska-Bartosz
- Department of Biochemistry and Cell Biology; University of Rzeszow; ul. Zelwerowicza 4; Rzeszow; 35-601; Poland
| |
Collapse
|
22
|
Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci 2013; 14:6981-7015. [PMID: 23535335 PMCID: PMC3645673 DOI: 10.3390/ijms14046981] [Citation(s) in RCA: 106] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2013] [Revised: 03/07/2013] [Accepted: 03/11/2013] [Indexed: 12/15/2022] Open
Abstract
The pineal hormone melatonin exerts its influence in the periphery through activation of two specific trans-membrane receptors: MT1 and MT2. Both isoforms are expressed in the islet of Langerhans and are involved in the modulation of insulin secretion from β-cells and in glucagon secretion from α-cells. De-synchrony of receptor signaling may lead to the development of type 2 diabetes. This notion has recently been supported by genome-wide association studies identifying particularly the MT2 as a risk factor for this rapidly spreading metabolic disturbance. Since melatonin is secreted in a clearly diurnal fashion, it is safe to assume that it also has a diurnal impact on the blood-glucose-regulating function of the islet. This factor has hitherto been underestimated; the disruption of diurnal signaling within the islet may be one of the most important mechanisms leading to metabolic disturbances. The study of melatonin–insulin interactions in diabetic rat models has revealed an inverse relationship: an increase in melatonin levels leads to a down-regulation of insulin secretion and vice versa. Elucidation of the possible inverse interrelationship in man may open new avenues in the therapy of diabetes.
Collapse
|